Applying CE and microchip CE to molecular cancer analysis: From research to clinical utility

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F13%3A%230000193" target="_blank" >RIV/26475821:_____/13:#0000193 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Applying CE and microchip CE to molecular cancer analysis: From research to clinical utility

Popis výsledku v původním jazyce

A poster demonstrating the use of CE and chip CE in analysis of various molecular cancer markers Decisions in clinical oncology are growingly relying on modern tools and technologies coming from genome research. Currently, several treatment options are available to most patients suffering from common forms of solid cancers (e.g.colorectal, lung, pancreas ...). The clinical decision is taken based on the extent of the tumor defined by TNM (tumor, nodes, metastasis) or other types of staging. The treatment options usually include surgical removal of tumorous tissue, irradiation of the tumor, pharmacological chemotherapy or a combination thereof. Assessment of the disease prognosis is often the key component in the decision process. A number of molecularaberrations found in cancerous tissue such as DNA mutations, gene amplifications or DNA hypermethylation may be utilized as biomarkers defining the disease prognosis. Such molecular markers may also be used to predict the likelihood of a

Název v anglickém jazyce

Applying CE and microchip CE to molecular cancer analysis: From research to clinical utility

Popis výsledku anglicky

A poster demonstrating the use of CE and chip CE in analysis of various molecular cancer markers Decisions in clinical oncology are growingly relying on modern tools and technologies coming from genome research. Currently, several treatment options are available to most patients suffering from common forms of solid cancers (e.g.colorectal, lung, pancreas ...). The clinical decision is taken based on the extent of the tumor defined by TNM (tumor, nodes, metastasis) or other types of staging. The treatment options usually include surgical removal of tumorous tissue, irradiation of the tumor, pharmacological chemotherapy or a combination thereof. Assessment of the disease prognosis is often the key component in the decision process. A number of molecularaberrations found in cancerous tissue such as DNA mutations, gene amplifications or DNA hypermethylation may be utilized as biomarkers defining the disease prognosis. Such molecular markers may also be used to predict the likelihood of a

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13638" target="_blank" >NT13638: Klinický význam vyšetření epigenetických faktorů pro zpřesnění diagnostiky, odhadu prognózy a rizika rekurence po kurativní resekci karcinomu pankreatu.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů